Franklin Biotechnology Discovery Fund Advisor Class (FTDZX)

Fund Assets	947.88M
Expense Ratio	0.80%
Min. Investment	$1,000
Turnover	35.87%
Dividend (ttm)	0.42
Dividend Yield	0.34%
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	n/a

Previous Close	153.59
YTD Return	17.29%
1-Year Return	35.26%
5-Year Return	48.86%
52-Week Low	105.16
52-Week High	159.01
Beta (5Y)	n/a
Holdings	91
Inception Date	Sep 1, 2009

About FTDZX

Under normal market conditions, the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

• Fund Family: Franklin Templeton Investments
• Category: Health
• Performance Rating: Below Average
• Risk Rating: Above Average
• Stock Exchange: NASDAQ
• Ticker Symbol: FTDZX
• Index: NASDAQ Biotechnology CR

Performance

FTDZX had a total return of 35.26% in the past year. Since the fund's inception, the average annual return has been 11.41%, including dividends.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
FRBRX	Class R6	0.69%
FBDIX	Class A	1.05%
FBTDX	Class C	1.80%

Top 10 Holdings

43.55% of assets

Name	Symbol	Weight
Amgen Inc.	AMGN	8.19%
Regeneron Pharmaceuticals, Inc.	REGN	7.14%
Vertex Pharmaceuticals Incorporated	VRTX	6.04%
Insmed Incorporated	INSM	3.76%
Ascendis Pharma A/S	ASND	3.61%
Gilead Sciences, Inc.	GILD	3.27%
Intra-Cellular Therapies, Inc.	ITCI	2.97%
Biogen Inc.	BIIB	2.93%
AstraZeneca PLC	AZN	2.83%
Merus N.V.	MRUS	2.82%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 20, 2022	$0.4163	Dec 20, 2022
Dec 15, 2021	$18.0843	Dec 15, 2021
Dec 15, 2020	$10.3921	Dec 15, 2020
Dec 16, 2019	$14.1643	Dec 18, 2019
Dec 17, 2018	$4.5496	Dec 19, 2018
Dec 15, 2017	$3.5969	Dec 19, 2017